Bevacizumab: 111 Real Stories

111 stories match bevacizumab. 109 of them mention chemotherapy.

Cancer Stories

A patient, who was diagnosed with Stage IV Colorectal CancerColorectal Cancer

Severe immune thrombocytopenia during treatment for metastatic colon cancer

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: KRAS-mutated; microsatellite stable; BRAF-wild type.

Metastatic Site: bilateral ovaries; pelvis; peritoneum; mesenteric…

After multiple metastatic recurrences and treatment changes, she died from progressive colon cancer; oxaliplatin had been permanently stopped after antibody-confirmed immune thrombocytopenia.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

Bilateral adrenal bleeding during bevacizumab treatment for metastatic colon cancer

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: RAS-mutant; BRAF-wild type; microsatellite stable.

Metastatic Site: peritoneum; liver; lung

Despite multiple systemic and local treatments, his metastatic colon cancer progressed in the liver and peritoneum, and he died from disease progression in November 2018.

PubMed Central
OutcomeIn Memory
Lee, who was diagnosed with Stage IV Colorectal CancerColorectal Cancer

Stage IV Colorectal Cancer: Lee's Survivor Story

Patient Info: Lee Jones, Male, 50s | Stage IV

Metastatic Site: Liver

As of February 2021, Lee reported no evidence of colon cancer since 2011 after treatment for Stage IV colon cancer with liver metastases, recurrence, chemotherapy, colon surgery, and liver surgery.

The Patient Story
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Ovarian AdenocarcinomaOvarian Cancer

Kidney Complications After Treatment for Stage IV Ovarian Cancer

Patient Info: Anonymized, Female, 60s | Stage IV

Metastatic Site: peritoneum|left lymph node

No further ovarian-cancer progression was observed during the 10 months after kidney biopsy. The nephrotic syndrome reached partial remission after immunosuppressive treatment was stopped and supportive care continued.

PubMed Central
OutcomeStable Disease
A patient, who was diagnosed with Stage III Colorectal CancerColorectal Cancer

Colon Cancer With an MLH1 Deletion and Lynch Syndrome

Patient Info: Anonymized, Male, Under 40 | Stage III

Biomarkers: dMMR with loss of MLH1 and PMS2. Familial MLH1 c.1057_1060delGCTG frameshift deletion identified; its clinical significance had not previously been reported.

The colon cancer progressed rapidly despite postoperative and second-line therapy, and he died from multiple organ failure one week after pembrolizumab was started.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Stage IV Mucinous Lung Cancer Treated With Afatinib and Surgery

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: CD74-NRG1 fusion; ALK/ROS1/EGFR/BRAF/KRAS/MET/HER2 wild type; PD-L1 initially not expressed and later 0%-20%

Metastatic Site: bilateral lungs|bone|right adrenal gland

She was alive and receiving treatment after bone and right-adrenal progression at the latest follow-up.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Lung AdenocarcinomaLung Cancer

Recurrent Mucinous Lung Cancer With Dose-Dependent Afatinib Responses

Patient Info: Anonymized, Female, Under 40 | Stage Metastatic/Advanced

Biomarkers: SDC4-NRG1 fusion; PD-L1 not expressed; low tumor mutation burden

Metastatic Site: bilateral lungs

She had progressive lung disease after several targeted-treatment attempts and was receiving paclitaxel with bevacizumab as of February 2020.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

Treatment-Related Inflammation Mimicked Metastatic Colon Cancer Recurrence

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: KRAS mutation

Metastatic Site: liver|peritoneum

Biopsy showed that new lymph-node, liver, and spleen findings were a treatment-related sarcoid-like reaction rather than recurrence, and 18 months of surveillance found no evidence of cancer.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

Metastatic Colon Cancer With KRAS, NRAS, and BRAF Mutations

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: KRAS exon 3 ; NRAS exon 2 ; BRAF exon 10 ; PIK3CA exon 2 .

Metastatic Site: liver

The liver metastases progressed despite FOLFOX and bevacizumab, and he died within one year of the initial diagnosis.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Lung Squamous Cell CarcinomaLung Cancer

Lung Cancer Metastasis to the Iris Treated With Bevacizumab

Patient Info: Anonymized, Male, 60s | Stage IV

Metastatic Site: right iris

The iris lesion and eye symptoms improved after bevacizumab, but he later died from systemic complications of metastatic lung cancer.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Osimertinib Improved Spinal Cord Metastases in Long-Standing Lung Cancer

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: Initial surgical specimen: no detected EGFR mutation and ALK-negative. Later pleural-fluid tumor: acquired EGFR T790M mutation with no other detected EGFR mutation.

Metastatic Site: cervical and mediastinal lymph nodes; bone; brain;…

Osimertinib improved neurologic function and kept the lung cancer stable for 14 months; he later died from bacterial pneumonia.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Lung AdenocarcinomaLung Cancer

Hormone Problems During Nivolumab Treatment for Advanced Lung Cancer

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: EGFR/ALK/ROS1/BRAF wild type

Metastatic Site: abdominal wall|brain

She was living with Stage IVA lung cancer after about 1 year of nivolumab. Thyroid levels normalized after levothyroxine adjustment, and continued endocrine monitoring was planned for treatment-related pituitary dysfunction.

PubMed Central
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

HER2-amplified metastatic colon cancer treated with afatinib after several therapies

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: RAS wild-type; BRAF wild-type; HER2 amplification; HER2 mutation

Metastatic Site: liver|abdominal wall|lung

After multiple treatment lines and a 3-month period of stable disease on afatinib, the cancer progressed again. He died in January 2018 from severe lung infection and kidney failure.

PubMed Central
OutcomeIn Memory
AO
Ovarian Cancer

Advanced Ovarian Cancer Presenting With Dermatomyositis

Patient Info: Anonymized, Female, 50s

Biomarkers: CA-125 3169 at diagnosis; later CA-125 rise with progression

After a partial response to second-line chemotherapy, nodal disease progressed again 5 months later and liposomal doxorubicin was planned.

PubMed Central
OutcomeSetback / Progression
OC
Ovarian Cancer

Ovarian Cancer With Pleural Spread and Recurrent Dermatomyositis

Patient Info: Anonymized, Female, 40s | Stage Metastatic/Advanced

Metastatic Site: pleura

She had symptomatic improvement after 2 cycles of carboplatin and liposomal doxorubicin for recurrent disease.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Colorectal AdenocarcinomaColorectal Cancer

Rectal Cancer Spreading to the Thyroid and Bones

Patient Info: Anonymized, Male, 40s | Stage Metastatic/Advanced

Biomarkers: CEA 2.75 ng/mL at diagnosis

Metastatic Site: thyroid|bones

His metastatic disease worsened after 3 cycles of bevacizumab and capecitabine. He declined further treatment and died at home within 2 months.

PubMed Central
OutcomeIn Memory
Patricia, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

Stage IV Colorectal Adenocarcinoma: Patricia's Patient Story

Patient Info: Patricia, 50s | Stage IV

Living with Stage IV colorectal cancer after about 6.5 years of intermittent chemotherapy and multiple local treatments; on a treatment holiday while awaiting December 2024 scans.

Our Cancer Stories
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Bilateral Breast Cancers Followed by Metastatic Disease and Long Eribulin Treatment

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: Left primary: ER 90%, HER2 FISH not amplified, Ki67 25%. Right primary: ER 90%

Metastatic Site: lung, pleura, liver, bone

After pelvic bone metastases appeared in 2017, she stopped eribulin, received pelvic radiation and remained on fulvestrant treatment.

PubMed Central
OutcomeCare Ongoing